专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09096537B1 Compositions and methods for the treatment of mucositis 有权
标题翻译：用于治疗粘膜炎的组合物和方法
公开(公告)号：US09096537B1
公开(公告)日：2015-08-04
申请号：US14587029
申请日：2014-12-31
申请人： Mahesh Kandula
发明人： Mahesh Kandula
IPC分类号： C07D233/44 , C07D307/68 , C07C53/126 , C07C229/28
CPC分类号： C07D233/44 , C07C53/126 , C07C69/60 , C07C229/08 , C07C229/28 , C07C229/46 , C07C2601/14 , C07D233/50 , C07D307/68
摘要： The invention relates to the compounds of formula I, formula II, formula III and formula IV or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III or formula IV and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucositis and oral mucosal inflammatory or oral infectious diseases.
摘要翻译：本发明涉及式I，式II，式III和式IV的化合物或其药学上可接受的多晶型物，溶剂合物，对映体，立体异构体和水合物。包含有效量的式I，式II，式III或式IV化合物的药物组合物和治疗粘膜炎的方法可以配制成口服，口腔，直肠，局部，透皮，经粘膜，静脉内，口服溶液，口腔粘膜层片，肠胃外给药，糖浆或注射。这样的组合物可用于治疗粘膜炎和口腔粘膜炎症或口腔传染病。

2. 发明授权

US09062006B2 High molecular weight polylactic acid synthesized via polycondensation catalyzed by bionic creatinine guanidinium chloride 有权
标题翻译：通过由仿生肌酐氯化胍催化的缩聚合成的高分子量聚乳酸
公开(公告)号：US09062006B2
公开(公告)日：2015-06-23
申请号：US14129323
申请日：2011-11-02
申请人： Hong Li , Quanxing Zhang , Wei Huang , Wei Jiang , Xupeng Zong , Bingcai Pan
发明人： Hong Li , Quanxing Zhang , Wei Huang , Wei Jiang , Xupeng Zong , Bingcai Pan
IPC分类号： C08G63/87 , C07D233/50 , A61L27/18 , A61L31/06 , A61K47/34 , A61L17/12 , C07D233/32 , C08G63/06
CPC分类号： C07D233/50 , A61K47/34 , A61L17/12 , A61L27/18 , A61L31/06 , C07D233/32 , C07D233/46 , C07D233/88 , C08G63/06 , C08G63/87
摘要： Disclosed is a high molecular weight polylactic acid synthesized by using a method for synthesizing and catalytically-polycondensing bionic creatinine-guanidinium chloride. Creatinine is used as the material in a reaction with aqueous hydrochloric acid to synthesize a bionic creatinine-guanidinium salt catalyst, creatinine-guanidinium chloride (CR.Cl). The creatinine-guanidinium chloride synthesized is used as a catalyst, an industrial grade lactic acid (LA, 85% to 90%, aqueous solution) is used as a monomer, a solvent-free two-step polycondensation method is used to synthesize and afford metal-free and toxic residue-free polylactic acid featuring high biological safety and high molecular weight.
摘要翻译：本发明公开了一种通过使用合成和催化缩聚仿生肌酐 - 氯化胍的方法合成的高分子量聚乳酸。使用肌酸酐作为与盐酸水溶液反应的材料，以合成肌酸酐 - 胍盐催化剂，肌酸酐 - 氯化胍（CR.Cl）。使用合成的肌酸胍 - 氯化胍作为催化剂，使用工业级乳酸（LA，85％〜90％，水溶液）作为单体，使用无溶剂的两步缩聚法合成并提供无金属和无毒无残留的聚乳酸，具有高生物安全性和高分子量。

3. 发明授权

US08815923B2 Therapeutic compounds 有权
标题翻译：治疗化合物
公开(公告)号：US08815923B2
公开(公告)日：2014-08-26
申请号：US13853160
申请日：2013-03-29
申请人： Allergan, Inc.
发明人： Santosh C. Sinha , Smita S. Bhat , Todd M. Heidelbaugh , Daniel W. Gil , Ken Chow , Michael E. Garst
IPC分类号： A61K31/421 , A61K31/426 , A61K31/4168 , C07D233/02 , C07D263/04 , C07D277/04 , C07D277/18 , C07D263/28 , C07D233/44 , C07D233/50
CPC分类号： C07D233/44 , C07D233/50 , C07D263/28 , C07D277/18
摘要： Disclosed herein is a compound having a structure compositions, methods, and medicaments related thereto are also disclosed.
摘要翻译：本文公开了具有与其有关的结构组成，方法和药物的化合物也被公开。

4. 发明申请

US20130210769A1 COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY 审中-公开
公开(公告)号：US20130210769A1
公开(公告)日：2013-08-15
申请号：US13840673
申请日：2013-03-15
申请人： Hong Liu , Xiaohui He , Dean Paul Phillips , Xuefeng Zhu , Kunyong Yang , Thomas Lau , Baogen Wu , Yongping Xie , Truc Ngoc Nguyen , Xing Wang
发明人： Hong Liu , Xiaohui He , Dean Paul Phillips , Xuefeng Zhu , Kunyong Yang , Thomas Lau , Baogen Wu , Yongping Xie , Truc Ngoc Nguyen , Xing Wang
IPC分类号： C07D265/32 , C07D263/20 , C07F7/18 , C07D233/74 , C07D233/32 , C07D207/26 , C07D233/38
CPC分类号： C07D265/32 , C07D207/26 , C07D207/40 , C07D233/12 , C07D233/16 , C07D233/32 , C07D233/38 , C07D233/42 , C07D233/46 , C07D233/50 , C07D233/52 , C07D233/74 , C07D263/20 , C07D263/22 , C07D285/06 , C07D403/04 , C07D403/06 , C07D403/14 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07F7/1804
摘要： The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).

5. 发明授权

US08354116B2 Bifunctional synthetic molecules 有权
标题翻译：双功能合成分子
公开(公告)号：US08354116B2
公开(公告)日：2013-01-15
申请号：US11820172
申请日：2007-06-18
申请人： Stephen G. Carter , Kanu Patel , Zhen Zhu , Lixin Qiao
发明人： Stephen G. Carter , Kanu Patel , Zhen Zhu , Lixin Qiao
IPC分类号： A61K9/00 , A61K8/02
CPC分类号： C07D213/80 , C07C69/612 , C07C233/87 , C07C2601/14 , C07D207/16 , C07D217/26 , C07D233/06 , C07D233/24 , C07D233/50 , C07D417/04
摘要： The synthesis and use of bifunctional molecules to improve the topical and transdermal delivery efficiency of various types of therapeutic agents or agents designed to promote the transdermal delivery of those therapeutic agents either into the skin tissue or into the systemic circulation. Three major classes of molecules are covalently joined as bifunctional substances; chemical vasodilators, passive dermal penetration enhancers and therapeutic or diagnostic drugs. Chemical vasodilators may be delivered into the skin to increasing the blood flow in a tissue that has compromised circulation or they may be used as part of a delivery vehicle to promote the delivery of the drug. Passive dermal penetration enhancers are those chemicals that promote the passive penetration of drugs and other chemicals through the stratum corneum and epidermis of the skin tissue. Drugs and diagnostic agents are the third group of chemicals that are candidates for the linkage of molecules.
摘要翻译：双功能分子的合成和使用以改善各种类型治疗剂或试剂的局部和透皮递送效率，所述治疗剂或试剂旨在促进将这些治疗剂透皮递送至皮肤组织或进入体循环。三大类分子共价连接成双功能物质; 化学血管扩张剂，被动皮肤渗透增强剂和治疗或诊断药物。化学血管扩张剂可以被递送到皮肤中以增加已经损害循环的组织中的血液流动，或者它们可以用作递送载体的一部分以促进药物的递送。被动皮肤渗透增强剂是促进药物和其他化学物质通过角质层和皮肤组织表皮的被动穿透的化学物质。药物和诊断剂是作为分子连接的候选物的第三组化学品。

6. 发明申请

US20110178144A1 THERAPEUTIC COMPOUNDS 失效
公开(公告)号：US20110178144A1
公开(公告)日：2011-07-21
申请号：US12673351
申请日：2008-08-14
申请人： Santosh C. Sinha , Smit S. Bhat , Todd M. Heidelbaugh , Daniel W. Gil , Ken Chow , Michael E. Garst
发明人： Santosh C. Sinha , Smit S. Bhat , Todd M. Heidelbaugh , Daniel W. Gil , Ken Chow , Michael E. Garst
IPC分类号： A61K31/4168 , C07D233/50 , A61P29/00 , A61P27/02
CPC分类号： C07D233/44 , C07D233/50 , C07D263/28 , C07D277/18
摘要： Disclosed herein is a compound having a structure compositions, methods, and medicaments related thereto are also disclosed.

7. 发明授权

US07799784B2 Quinoxaline derivatives of alpha-2 adrenergic agonists 失效
标题翻译： α-2肾上腺素能激动剂的喹喔啉衍生物
公开(公告)号：US07799784B2
公开(公告)日：2010-09-21
申请号：US12162529
申请日：2007-02-02
申请人： Francesca Benedini , Francesco Impagnatiello , Stefano Biondi , Ennio Ongini , Wesley Kwan Mung Chong
发明人： Francesca Benedini , Francesco Impagnatiello , Stefano Biondi , Ennio Ongini , Wesley Kwan Mung Chong
IPC分类号： A61K31/495
CPC分类号： C07D233/50 , C07D239/76
摘要： The present invention relates to alpha2-adrenergic receptor agonist nitrooxyderivatives, including the following structure, having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of ocular diseases, in particular high intraocular pressure and glaucoma.
摘要翻译：本发明涉及具有改善的药理活性和增强的耐受性的α2-肾上腺素能受体激动剂硝基氧化酶，包括以下结构。它们可用于治疗眼部疾病，特别是高眼内压和青光眼。

8. 发明申请

US20090088472A1 Protective Agent for Neuronal Cell Comprising Amidino Derivative as Active Ingredient 审中-公开
标题翻译：包含脒衍生物作为活性成分的神经元细胞的保护剂
公开(公告)号：US20090088472A1
公开(公告)日：2009-04-02
申请号：US11920406
申请日：2006-05-17
申请人： Kouji Oohashi , Reina Doi , Masaaki Kageyama
发明人： Kouji Oohashi , Reina Doi , Masaaki Kageyama
IPC分类号： A61K31/24 , C07C229/54 , A61P27/02
CPC分类号： C07D233/50 , A61K31/245 , A61K31/4168
摘要： An object of the present invention is to provide a protective agent for a neuronal cell. The protective agent for a neuronal cell according to the present invention contains a compound represented by the following general formula [I] or a salt thereof as an active ingredient. In the formula, R1, R2 and R3 are the same or different and represent a hydrogen atom or an alkyl group, or R1 and R3 may be joined together to form a ring having one or more double bonds.
摘要翻译：本发明的目的是提供一种用于神经元细胞的保护剂。本发明的神经元细胞保护剂含有下述通式[I]表示的化合物或其盐作为有效成分。在该式中，R 1，R 2和R 3相同或不同，表示氢原子或烷基，或者R 1和R 3可以连接在一起形成具有一个或多个双键的环。

9. 发明申请

US20070135505A1 Aralkyl ester soft drugs 审中-公开
标题翻译：芳烷酯软药
公开(公告)号：US20070135505A1
公开(公告)日：2007-06-14
申请号：US11652365
申请日：2007-01-11
申请人： Paul Erhardt
发明人： Paul Erhardt
IPC分类号： A61K31/4164 , A61K31/4166
CPC分类号： C07D451/06 , A61K9/0048 , A61K31/4164 , A61K31/4166 , A61K45/06 , C07D209/28 , C07D211/90 , C07D223/22 , C07D233/50 , C07D233/76 , C07D261/16 , C07D277/56 , C07D401/06 , C07D405/12 , C07D473/06 , C07D475/08 , A61K2300/00
摘要： The present invention describes a method for programming a specific course and rate of metabolism for a parent drug compound that leads to an inactive or very weakly active and nontoxic metabolite when the modified drug compound is administered. The parent drug compound is modified by forming one or more of a predetermined chemical arrangement within the parent drug structure where the chemical arrangement is A-Φ-R—X—R′; where A is absent or is a tether moiety which allows for a metabolically stable chemical connection to be made to the parent drug compound; Φ is a substituted aryl or heteroaryl system that is already present within the parent drug compound or is specifically added to the parent drug compound via A; R is an alkyl or alkene containing chain either branched or unbranched from 0 to 10 carbons that is either also already present within the parent drug compound or is specifically added to the parent drug compound via connection to Φ; X is a carboxyl, sulfoxyl or phosphatyl function that is specifically added to the parent drug compound via connection to R; and, R′ is an added alkyl, alkenyl, or aralkyl group either branched or unbranched containing from 1 to 10 carbons, other common leaving group, or a structural element already present as an inherent portion of the parent drug compound.
摘要翻译：本发明描述了当施用改性药物化合物时，导致导致非活性或非常弱活性和无毒代谢物的母体药物的特定途径和代谢速率的方法。母体药物化合物通过在化学排列是A-Phi-R-X-R'的母体药物结构内形成预定化学排列中的一种或多种进行改性; 其中A不存在或是能够与母体药物化合物进行代谢稳定的化学连接的系链部分; Phi是已经存在于母体药物中的取代的芳基或杂芳基体系，或通过A特异性地添加到母体药物化合物中; R是含有0〜10个碳原子的支链或不含支链的烷基或烯烃，其也已经存在于母体药物化合物中，或通过与Phi连接而特异性地添加到母体药物化合物中; X是通过与R连接而特异性地添加到母体药物化合物中的羧基，亚砜基或磷酰基官能团; R'是含有1至10个碳的支链或非支链的烷基，链烯基或芳烷基，其它常用的离去基团或已经作为母体药物化合物的固有部分存在的结构元件。

10. 发明申请

US20060004075A1 Substituted aryl amides as IP antagonists 失效
标题翻译：取代的芳基酰胺作为IP拮抗剂
公开(公告)号：US20060004075A1
公开(公告)日：2006-01-05
申请号：US11217526
申请日：2005-09-01
申请人： Paul Keitz , Alam Jahangir , Francisco Lopez-Tapia , Counde O'Yang
发明人： Paul Keitz , Alam Jahangir , Francisco Lopez-Tapia , Counde O'Yang
IPC分类号： A61K31/4172 , C07D233/44
CPC分类号： C07D401/12 , C07D233/50 , C07D403/12 , C07D405/12 , C07D409/12
摘要： Compounds effective as IP receptor modulators, particularly IP receptor antagonists, that are of the formula I: wherein A, R1, R2, R3 and R4 are as defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. Also disclosed are pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.
摘要翻译：作为IP受体调节剂，特别是IP受体拮抗剂有效的化合物，其具有式I：其中A，R 1，R 2，R 3， >和R 4>如说明书中所定义; 和各异构体，异构体的外消旋或非外消旋混合物及其药学上可接受的盐或溶剂合物。还公开了含有这些化合物的药物组合物及其用作治疗剂的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式